Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.
TREATMENT OF CHILDREN WITH HISTIOCYTOSIS
β Scribed by M. M. Reid; G. R. Burgio; M. Aricog; M. Marconi; A. Lanfranchi; D. Caselli; A. G. Ugazio
- Book ID
- 114712084
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 171 KB
- Volume
- 75
- Category
- Article
- ISSN
- 0007-1048
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Viana et al. [I] described their experience with etoposide (VP-16) as initial therapy in the management of patients with Langerhans cell histiocytosis (LCH). However, caution should be used in advocating the use of an epipodophyllotoxin as the "drug of choice" for the treatment of this disorder. Alt
## Abstract Fiftyβtwo pediatric patients with Langerhans cell histiocytosis (LCH) were diagnosed at the Emma Kinderziekenhuis (EKZ) in Amsterdam over a 20βyear period. Eight patients with multiorgan involvement with organ dysfunction and ten patients with multiorgan involvement without organ dysfun